Germany: Biopharmaceutical Production Sartorius Joins German Research Center for AI as New Shareholder
The German Research Center for Artificial Intelligence (DFKI) welcomed Sartorius as its new shareholder and together the companies plan to extend their partnership to develop future-focused tools and AI applications for the production of advanced medications.
Göttingen/Germany – Sartorius has recently joined the group of shareholders of the German Research Center for Artificial Intelligence (DFKI). The Göttingen-based life science group and DFKI have already been working together for some time in a joint research laboratory on the development of future-focused tools and AI applications for the production of advanced medications.
“We are happy to take the next step in our partnership with Sartorius and look forward to extending it even further. At a time when research and development in medicine and biopharma is especially at the focus, the commitment of a successful global player like Sartorius as a regular DFKI partner underscores the high significance of our AI technologies for this important field,” said Professor Antonio Krüger, Ph.D., the Managing Director and Head of the Cognitive Assistants Research Department at DFKI.
“I am convinced that this partnership will result in important innovations for our industry. AI can unfold its powerful capabilities, above all in the accelerated development of more efficient medical drug manufacturing processes. In the medium term, we moreover see the potential of using AI processes to develop active pharmaceutical ingredients faster and more cost-effectively than the time consuming and cost intensive trial and error processes that are common today, thus making new therapeutics available earlier and to more patients,” stated Dr. Joachim Kreuzburg, Executive Board Chairman and CEO of Sartorius.
KI Tools for Biopharmaceutical Production
Sartorius and DFKI are currently conducting research on deep learning algorithms and methods for image recognition of cells and organoids, analysis and modeling of biological systems, and for simulation and optimisation of biopharmaceutical production processes.
In August 2019, DFKI and Sartorius had opened the Sartorius AI Lab (Sail) on the DFKI campus. At this joint research laboratory, the use of artificial intelligence in Sartorius products and platform solutions is experimentally tested and further developed. As an independent laboratory and a protected data space, ‘Sail’ is also available to Sartorius cooperation partners and customers. The lab is also successfully used for mutual training: Specialists from Sartorius work in the DFKI research ecosystem and, for example, use its deep learning hardware and expertise. In return, DFKI scientists benefit from Sartorius’ expertise in life sciences. ‘Sail’ is now being further extended, inter alia, by a special ‘wet lab,’ which is a laboratory in which novel AI processes are combined directly with cellular and molecular biology experiments and can be practically tested.
“AI will certainly have a significant impact on life science research in the future and will enable fundamentally new research approaches and methods. However, unlike other applications in the consumer goods branch or IT sector, the application of AI tools in life sciences is still in its infancy, as the combination of application expertise and AI knowledge is a much greater challenge due to the complex biological interrelationships and interactions. In this context, the ‘Sail’ wet lab in which biologists and data scientists can conduct experiments and research together is a further step to enable faster, more efficient biomedical and biopharmaceutical research and development,” added Professor Oscar-Werner Reif, Ph.D., Chief Technology Officer at Sartorius.
Professor Andreas Dengel, Ph.D., the Executive Director of DFKI in Kaiserslautern and Head of the Smart Data & Knowledge Services Research Department, commented: “It is important to us to put industry-relevant AI technologies to sustainable use. Our transfer labs and joint projects with our industrial partners and shareholders enable us to accomplish this. We are pleased to cement our collaboration with Sartorius in which we are already successfully working on the use of AI tools to optimise biopharmaceutical production processes.”
Expansion of the Prominent Group of DFKI Shareholders
Sartorius is the first life science company to join the group of DFKI shareholders as its 33rd member and has received a seat on the Supervisory Board. This role is filled by Chief Technology Officer Dr. Oscar-Werner Reif. Additional shareholders of DFKI include numerous renowned companies of various industrial branches: Accenture, Airbus, Bilfinger Digital Next, BMW, Cerence, Claas, Daimler, Deutsche Börse, Deutsche Messe, Deutsche Telekom, Fraunhofer Gesellschaft, Google, Harting, Intel, John Deere, KIBG, Microsoft Deutschland, Munich Re, Nvidia, Ricoh, Robert Bosch, Rosen Swiss, SAP, Schwarz-Gruppe, Software, Volkswagen, VSE and ZF Friedrichshafen, as well as the universities of the DFKI locations in Bremen, Kaiserslautern and Saarbrücken.